Long-acting somatostatin analog controls acid and gastrin secretion in benign, not in malignant, Zollinger-Ellison syndrome.

Abstract

The long-acting somatostatin (SMS) analog, SMS 201-995 has beneficial effects on APUDomas. In two Zollinger-Ellison syndrome (ZES) patients we assessed basal acid output (BAO) and 24-h pH under SMS and compared them to controls. We also assessed total gastrin, gastrin 17, insulin, glucagon, C-peptide, and SMS by radioimmunoassay. In the benign gastrinoma, an acid-controlling action of SMS was shown, elevating the 24-h pH threshold over the pH range 1.5-5 of 55-10% compared with control. A parallel inhibition of the gastrins greater than 90% was apparent. We found no beneficial effect on gastric acid secretion and on tumor gastrin in the malignant gastrinoma despite a fourfold higher plasma SMS level. Non-tumor-related peptides were suppressed by approximately 50% and in contrast to gastrin they again reached pre-SMS levels before the next dose of the drug. We conclude that SMS is more effective in benign than in malignant gastrinomas, and may be exclusively so.

• Authors: F E Bauer, M Hummel, H S Merki, E Schulz, R Oeder, P Marbach
• Journal: Journal of clinical gastroenterology (J Clin Gastroenterol) Vol. 11 Issue 3 Pg. 282-6 (Jun 1989) ISSN: 0192-0790 [Print] United States
• PMID: 2754214 (Publication Type: Journal Article)

Chemical References

• Gastrins
• Octreotide

Topics

• Female
• Gastric Acid (metabolism)
• Gastrins (metabolism)
• Humans
• Hydrogen-Ion Concentration
• Male
• Middle Aged
• Octreotide (therapeutic use)
• Zollinger-Ellison Syndrome (drug therapy)